spacer
home > > autumn 2008 > more than a lifestyle drug
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
News and Press Releases

Oncology: Tollys earns ‘Best-in-class therapeutic innovation’ award from MATWIN for its drug candidate TL-532

Lyon, France, May 18, 2021 – Tollys, a biopharmaceutical company responsible for developing TL-532, the first anti-cancer immunotherapy based on a synthetic toll-like receptor 3 (TLR3) specific agonist, today announces that it has been awarded the ‘Best-in-Class Therapeutic Innovation’ prize by the MATWIN international board.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement